KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Equity Average (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Equity Average for 14 consecutive years, with $94.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 558.18% year-over-year to $94.2 million, compared with a TTM value of $94.2 million through Dec 2025, up 558.18%, and an annual FY2025 reading of $87.0 million, down 33.08% over the prior year.
  • Equity Average was $94.2 million for Q4 2025 at Travere Therapeutics, up from $53.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $347.5 million in Q2 2021 and bottomed at -$7.7 million in Q3 2024.
  • Average Equity Average over 5 years is $151.0 million, with a median of $133.1 million recorded in 2022.
  • The sharpest move saw Equity Average plummeted 103.86% in 2024, then soared 794.53% in 2025.
  • Year by year, Equity Average stood at $304.7 million in 2021, then tumbled by 76.45% to $71.8 million in 2022, then skyrocketed by 234.83% to $240.3 million in 2023, then crashed by 94.04% to $14.3 million in 2024, then soared by 558.18% to $94.2 million in 2025.
  • Business Quant data shows Equity Average for TVTX at $94.2 million in Q4 2025, $53.2 million in Q3 2025, and $32.8 million in Q2 2025.